- Home
- SKYE vs AEVA Comparison
SKYE vs AEVA Comparison
Compare SKYE & AEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- AEVA
- Stock Information
- Founded
- SKYE 2012
- AEVA 2019
- Country
- SKYE United States
- AEVA United States
- Employees
- SKYE N/A
- AEVA N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- AEVA Auto Parts:O.E.M.
- Sector
- SKYE Health Care
- AEVA Consumer Discretionary
- Exchange
- SKYE Nasdaq
- AEVA Nasdaq
- Market Cap
- SKYE 172.9M
- AEVA 177.0M
- IPO Year
- SKYE N/A
- AEVA N/A
- Fundamental
- Price
- SKYE $3.14
- AEVA $3.20
- Analyst Decision
- SKYE Strong Buy
- AEVA Buy
- Analyst Count
- SKYE 5
- AEVA 5
- Target Price
- SKYE $18.40
- AEVA $10.03
- AVG Volume (30 Days)
- SKYE 346.3K
- AEVA 255.1K
- Earning Date
- SKYE 11-09-2024
- AEVA 11-06-2024
- Dividend Yield
- SKYE N/A
- AEVA N/A
- EPS Growth
- SKYE N/A
- AEVA N/A
- EPS
- SKYE N/A
- AEVA N/A
- Revenue
- SKYE N/A
- AEVA $6,540,000.00
- Revenue This Year
- SKYE N/A
- AEVA $109.97
- Revenue Next Year
- SKYE N/A
- AEVA $136.96
- P/E Ratio
- SKYE N/A
- AEVA N/A
- Revenue Growth
- SKYE N/A
- AEVA 89.40
- 52 Week Low
- SKYE $1.44
- AEVA $2.20
- 52 Week High
- SKYE $19.41
- AEVA $7.25
- Technical
- Relative Strength Index (RSI)
- SKYE 29.03
- AEVA 60.21
- Support Level
- SKYE $5.03
- AEVA $2.85
- Resistance Level
- SKYE $5.89
- AEVA $3.05
- Average True Range (ATR)
- SKYE 0.60
- AEVA 0.22
- MACD
- SKYE -0.23
- AEVA 0.06
- Stochastic Oscillator
- SKYE 4.57
- AEVA 92.31
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.